| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-1352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-10043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-998
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-1394
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2302
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2303
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2307 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0647
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4702
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0789 |
| filingDate |
2019-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2022-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2022502091-A |
| titleOfInvention |
Acceleration of human hematopoietic stem cell differentiation into mature natural killer cells by enhancing antibody-dependent cellular cytotoxicity |
| abstract |
The invention generally relates to a method of differentiating human hematopoietic stem cells (HSCs) into mature natural killer (NK) cells. The method is particularly characterized in that mature NK cells are obtained very early in the differentiation process and these NK cells exhibit increased CD16 expression and antibody-dependent cellular cytotoxicity (ADCC) (FIG. 11). The method of the invention is to transfect and / or transduce HSCs with at least one transcription factor selected from T-Box expressed in T cells (T-BET) and Eomesodermin (EOMES), or a combination thereof. Especially included. [Selection diagram] Fig. 11 |
| priorityDate |
2018-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |